Biocartis and Fast-track Diagnostics Sign Strategic Collaboration
News May 27, 2015
Biocartis and Fast-track diagnostics have announced that they have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla™ system.
Biocartis and Fast-track diagnostics plan to collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broader range of disease pathogens in a single test. Most current methods focus on the detection of one or a few pathogens expected to be present in a patient sample.
If the sample is negative, a new test will be performed for other pathogens, increasing the time to result. With syndromic multiplex tests, the initial test will not just look for the most likely pathogen, but also for a range of less likely pathogens, preventing the need to retest.
As part of the collaboration, tests from Fast-track diagnostics’ comprehensive infectious disease menu will be developed for use on Biocartis’ innovative molecular diagnostics (MDx) platform, Idylla™. Idylla™ is a fully-automated MDx system that delivers accurate, rapid tests in virtually any setting, from virtually any biological sample type, and without the need for pre-processing or specialist training.
The first assay to be developed under the collaboration is a multiplex respiratory panel for the detection of viral and bacterial targets in upper respiratory tract infections. Financial details of the agreement are not disclosed.
Erik Vossenaar, VP Business Development of Biocartis, commented: “In line with our strategy to rapidly expand our test menu, we are excited to be collaborating with Fast-track diagnostics to further enhance our position in infectious diseases. By combining Fast-track diagnostics’ expertise and compelling portfolio of multiplex PCR panels with the multiplex capabilities and unique features of our Idylla system, we have formed a powerful combination to create tests that can identify multiple disease driving pathogens from a patient sample.”
Bill Carman, Chief Executive Officer of Fast-track diagnostics, commented: “Fast-track diagnostics is delighted to be collaborating with Biocartis. We are dedicated to developing high-quality, accurate multiplex PCR panels and look forward to working with the Biocartis team to develop a range of tests for the Idylla system.”
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE